ArticleScientific reports2025
Transaxillary vs. Transsubclavian Gasless endoscopic thyroidectomy approaches for papillary thyroid cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Initial experience with the Carina™ platform for gasless transaxillary robotic thyroidectomy in papillary thyroid carcinoma: an early feasibility report.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of transaxillary and transsubclavian approaches for endoscopic thyroidectomy has increased globally. However, studies examining the comparative outcomes of these procedures are scarce. In this study, we aimed to compare the safety and efficacy of thyroidectomy between the gasless endoscopic thyroidectomy transaxillary approach (GETTA) and gasless endoscopic thyroidectomy transsubclavian approach (GETTSA) in patients with papillary thyroid cancer (PTC). Medical records of patients with PTC who underwent GETTA or GETTSA performed by the same surgical team between August 2022 and August 2023 were retrospectively reviewed. Propensity score matching (PSM) was used to mitigate potential selection bias and adjust for baseline clinical characteristic differences. After PSM using 10 covariates, 196 patients (GETTA: 98; GETTSA: 98) were included. In comparison to the GETTSA group, the GETTA group exhibited a longer duration of operation (120.00 [103.75-140.00] vs. 110.00 [90.00-125.00] min, P = 0.001), longer postoperative hospital stays (1.00 [1.00-3.00] vs. 1.00 [1.00-2.00] days, P = 0.008), higher hospitalisation costs (23,973.02 [22,640.80-25,379.80] vs. 23,306.00 [21,968.97-24,070.68] Yuan, P = 0.015), and greater postoperative drainage (60.00 [50.00-70.00] vs. 46.50 [40.00-56.25] mL, P < 0.001). Intraoperative parathyroid autotransplantation and vocal cord paralysis rates were not significantly different between groups. The number of lymph node metastases via central lymph node dissection was not significantly different between groups (0.00 [0.00-1.00] vs. 0.00 [0.00-1.00], P = 0.645). No significant procedural safety or completeness differences were observed between GETTA and GETTSA. GETTA had better cosmetic outcomes. GETTSA had shorter duration of operation durations, shorter hospital stays, lower hospitalisation costs, and lower postoperative drainage, making it a better option for clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.